Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2025-12-01 00:00:00 ET · period of report 2025-09-05 · accession 0001193125-25-304177 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-01 | 2025-09-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.81 | -199 | 19.2K | -1% | -$360.19 | |
| 2025-12-01 | 2025-12-01 | MGX | Wein Matthew | See Remarks | A - Grant | $1.60 | +96.0K | 115.2K | +499% | +$153.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-05 | S | D | 199 | $1.81 | 19,230 | D | — | — | (F2) Includes 1,359 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 30, 2025 and 1,377 shares acquired under the Company's ESPP on November 28, 2025. |
| 2 | Common | Common Stock | 2025-12-01 | A | A | 96,000 | $1.60 | 115,230 | D | — | — |